[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100610139":3},{"organization":4,"armGroups":7,"interventions":18,"overallOfficials":28,"centralContacts":32,"locations":41,"responsibleParty":203,"collaborators":37,"id":205,"slug":206,"hasResults":207,"nctId":208,"briefTitle":209,"officialTitle":210,"acronym":211,"eligibilityCriteria":212,"healthyVolunteers":207,"sex":213,"minAge":214,"maxAge":37,"enrollmentInfo":215,"targetDuration":37,"studyType":218,"phases":219,"briefSummary":221,"conditions":222,"keywords":37,"overallStatus":44,"whyStopped":37,"lastUpdateSubmitDate":224,"lastUpdatePostDateStruct":225,"startDateStruct":228,"completionDateStruct":230,"leadSponsor":232,"locationsCount":233},{"fullName":5,"class":6},"Hoffmann-La Roche","INDUSTRY",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Afimkibart Group I","EXPERIMENTAL","Participants will receive Afimkibart as subcutaneous (SC) injection.",[13],"Drug: Afimkibart",{"label":15,"type":10,"description":16,"interventionNames":17},"Afimkibart Group II","Participants will receive Afimkibart as SC injection.",[13],[19],{"type":20,"name":21,"description":22,"armGroupLabels":23,"otherNames":24},"DRUG","Afimkibart","Afimkibart SC injection will be administered as per the schedule defined in the protocol.",[9,15],[25,26,27],"RO7790121","PF-06480605","RVT-3101",[29],{"name":30,"affiliation":5,"role":31},"Clinical Trials","STUDY_DIRECTOR",[33,39],{"name":34,"role":35,"phone":36,"phoneExt":37,"email":38},"Reference Study ID Number: CS45943 https:\u002F\u002Fforpatients.roche.com\u002F","CONTACT","888-662-6728 (U.S. and Canada)",null,"global-roche-genentech-trials@gene.com",{"name":40,"role":35,"phone":37,"phoneExt":37,"email":37},"Fastest response: use the inquiry form. No email attachments. https:\u002F\u002Fwww.gene.com\u002Fcontact-us\u002Fsubmit-medical-inquiry",[42,56,66,76,88,98,108,117,129,138,149,161,170,179,185,194],{"facility":43,"status":44,"city":45,"state":46,"zip":47,"country":48,"countryCode":49,"cosmosGeoPoint":50,"geoPoint":55,"contacts":37},"Hamilton Research, LLC","RECRUITING","Alpharetta","Georgia","30022","United States","US",{"type":51,"coordinates":52},"Point",[53,54],-84.29409,34.07538,{"lat":54,"lon":53},{"facility":57,"status":44,"city":58,"state":59,"zip":60,"country":48,"countryCode":49,"cosmosGeoPoint":61,"geoPoint":65,"contacts":37},"Revival Research Institute, LLC","Troy","Michigan","48084",{"type":51,"coordinates":62},[63,64],-83.14993,42.60559,{"lat":64,"lon":63},{"facility":67,"status":44,"city":68,"state":69,"zip":70,"country":48,"countryCode":49,"cosmosGeoPoint":71,"geoPoint":75,"contacts":37},"Best Skin Research LLC","Camp Hill","Pennsylvania","17011",{"type":51,"coordinates":72},[73,74],-76.91997,40.23981,{"lat":74,"lon":73},{"facility":77,"status":44,"city":78,"state":79,"zip":80,"country":81,"countryCode":82,"cosmosGeoPoint":83,"geoPoint":87,"contacts":37},"Centro de Estudos em Terapias Inovadoras ? CETI","Curitiba","Paraná","80030-110","Brazil","BR",{"type":51,"coordinates":84},[85,86],-49.27306,-25.42778,{"lat":86,"lon":85},{"facility":89,"status":44,"city":90,"state":91,"zip":92,"country":81,"countryCode":82,"cosmosGeoPoint":93,"geoPoint":97,"contacts":37},"Irmandade Da Santa Casa de Misericordia de Porto Alegre","Porto Alegre","Rio Grande do Sul","90020-090",{"type":51,"coordinates":94},[95,96],-51.23019,-30.03283,{"lat":96,"lon":95},{"facility":99,"status":44,"city":100,"state":101,"zip":102,"country":81,"countryCode":82,"cosmosGeoPoint":103,"geoPoint":107,"contacts":37},"Centro de Pesquisa São Lucas","Campinas","São Paulo","13060-803",{"type":51,"coordinates":104},[105,106],-47.06083,-22.90556,{"lat":106,"lon":105},{"facility":109,"status":44,"city":110,"state":37,"zip":111,"country":81,"countryCode":82,"cosmosGeoPoint":112,"geoPoint":116,"contacts":37},"Instituto Brasil de Pesquisa Clínica-IBPCLIN S\u002FA","Rio de Janeiro","20241-180",{"type":51,"coordinates":113},[114,115],-43.18223,-22.90642,{"lat":115,"lon":114},{"facility":118,"status":44,"city":119,"state":120,"zip":121,"country":122,"countryCode":123,"cosmosGeoPoint":124,"geoPoint":128,"contacts":37},"DermEffects","London","Ontario","N6H 5L5","Canada","CA",{"type":51,"coordinates":125},[126,127],-81.23304,42.98339,{"lat":127,"lon":126},{"facility":130,"status":44,"city":131,"state":120,"zip":132,"country":122,"countryCode":123,"cosmosGeoPoint":133,"geoPoint":137,"contacts":37},"DermEdge","Mississauga","L4Y4C5",{"type":51,"coordinates":134},[135,136],-79.6583,43.5789,{"lat":136,"lon":135},{"facility":139,"status":44,"city":140,"state":37,"zip":141,"country":142,"countryCode":143,"cosmosGeoPoint":144,"geoPoint":148,"contacts":37},"Dermatologikum Hamburg Gemeinschaftspraxis GbR","Hamburg","20354","Germany","DE",{"type":51,"coordinates":145},[146,147],9.99302,53.55073,{"lat":147,"lon":146},{"facility":150,"status":44,"city":151,"state":152,"zip":153,"country":154,"countryCode":155,"cosmosGeoPoint":156,"geoPoint":160,"contacts":37},"Centrum Medyczne Pratia Katowice I","Katowice","Silesian Voivodeship","40-081","Poland","PL",{"type":51,"coordinates":157},[158,159],19.02173,50.2597,{"lat":159,"lon":158},{"facility":162,"status":44,"city":163,"state":37,"zip":164,"country":154,"countryCode":155,"cosmosGeoPoint":165,"geoPoint":169,"contacts":37},"Centrum Medyczne Pratia Gdynia","Gdynia","81-338",{"type":51,"coordinates":166},[167,168],18.53188,54.51889,{"lat":168,"lon":167},{"facility":171,"status":44,"city":172,"state":37,"zip":173,"country":154,"countryCode":155,"cosmosGeoPoint":174,"geoPoint":178,"contacts":37},"Specjalistyczny Gabinet Dermatologiczny dr n. med. Pawel Brzewski","Krakow","30-002",{"type":51,"coordinates":175},[176,177],19.93658,50.06143,{"lat":177,"lon":176},{"facility":180,"status":44,"city":172,"state":37,"zip":181,"country":154,"countryCode":155,"cosmosGeoPoint":182,"geoPoint":184,"contacts":37},"Centrum Nowoczesnych Terapii \"Dobry Lekarz\"","31-011",{"type":51,"coordinates":183},[176,177],{"lat":177,"lon":176},{"facility":186,"status":44,"city":187,"state":37,"zip":188,"country":154,"countryCode":155,"cosmosGeoPoint":189,"geoPoint":193,"contacts":37},"Uniwersytecki Szpital Kliniczny im.Fryderyka Chopina w Rzeszowie","Rzeszów","35-055",{"type":51,"coordinates":190},[191,192],21.99901,50.04132,{"lat":192,"lon":191},{"facility":195,"status":44,"city":196,"state":37,"zip":197,"country":154,"countryCode":155,"cosmosGeoPoint":198,"geoPoint":202,"contacts":37},"Klinika Ambroziak Dermatologia","Warsaw","02-953",{"type":51,"coordinates":199},[200,201],21.01178,52.22977,{"lat":201,"lon":200},{"type":204,"investigatorFullName":37,"investigatorTitle":37,"investigatorAffiliation":37,"oldNameTitle":37,"oldOrganization":37},"SPONSOR","100610139","phase-2-a-long-term-extension-study-to-evaluate-the-safety-and-efficacy-of-afimkibart-ro7790121-in-participants-with-atopic-dermatitis-100610139",false,"NCT07223697","A Long Term Extension Study to Evaluate the Safety and Efficacy of Afimkibart (RO7790121) in Participants With Atopic Dermatitis","An Extension Study To Evaluate the Long-Term Safety and Efficacy of Afimkibart (RO7790121) in Patients With Atopic Dermatitis Who Participated in Previous Afimkibart Clinical Trials","Velarite-LTE","Inclusion Criteria:\n\n* Ability and willingness to comply with all aspects of the protocol including completion of the efficacy assessments (EASI and IGA), clinical outcome assessment instruments (DLQI, POEM), and safety and PK sample collections for the duration of the study\n\nParent Clinical Trial-Specific Criteria:\n\n* Study CS45570 participants who continued to be evaluated at the Week 36 follow up visit and achieved =\\> EASI50 response from study baseline\n\nExclusion Criteria:\n\n* Evidence of other skin conditions that would interfere with the assessment of AD\n* Withdrawal of consent and\u002For premature discontinuation from parent study\n* Any permanent discontinuation of study drug in parent study\n* History of severe allergic reaction or anaphylactic reaction to any biologic agent or known hypersensitivity to any component of Afimkibart","ALL","18 Years",{"count":216,"type":217},120,"ESTIMATED","INTERVENTIONAL",[220],"PHASE2","This study will assess long-term safety and efficacy of Afimkibart (also known as RO7790121) in participants with Atopic Dermatitis (AD) who participated in previous afimkibart clinical trials.",[223],"Atopic Dermatitis","2026-06-05",{"date":226,"type":227},"2026-06-09","ACTUAL",{"date":229,"type":227},"2026-01-08",{"date":231,"type":217},"2033-03-01",{"name":5,"class":6},16]